While several non-SMN pathways and molecular targets have been highlighted as being aberrantly regulated in SMA models and display therapeutic potential, these studies remain, for the most part, in the pre-clinical discovery phase, in contrast to SMN-dependent strategies that are quickly dominating the clinical trial landscape. Here, SMN2 is linked to proximal spinal muscular atrophy.